Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of May 2026. The report details the entry into a Material Definitive Agreement regarding a private placement of securities.
Key Financial Metrics
- Gross Proceeds: $3.5 million from the private placement.
- Capital Raised: Issuance of 3,500,000 Class A ordinary shares and 3,500,000 warrants.
- Warrant Terms: Exercise price of $1.00 per share; exercisable immediately; expire five years from issuance.
- Use of Proceeds: Working capital and general corporate purposes.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics.
Material Changes
On May 1, 2026, the Company entered into a Securities Purchase Agreement with several non-U.S. Persons. The transaction closed on May 2, 2026, resulting in the issuance of shares and warrants in exchange for gross proceeds of $3.5 million. This represents a significant capital event distinct from prior comparable periods which are not detailed in this specific filing.
Guidance, Outlook, and Risks
- Management Commentary: Proceeds are designated for working capital and general corporate purposes.
- Unusual Items: The warrants include a unique "Alternate Cashless Exercise" provision. Starting on the 7th calendar day following issuance, holders may exchange warrants for nine times the number of underlying shares instead of the standard cashless exercise formula.
- Risks and Contingencies: The offering was conducted under Regulation S, relying on representations that purchasers are not U.S. persons. The filing notes that the description of the agreement is qualified by reference to the full text of the attached exhibits.
Investor Verification Checklist
- Verify the exact net proceeds after deduction of customary expenses, as only gross proceeds ($3.5 million) are stated.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant form (Exhibit 4.1) to understand all covenants and the specific mechanics of the Alternate Cashless Exercise.
- Confirm the current share count and dilution impact of the 3,500,000 new shares and potential warrant exercises.
- Assess the Company's immediate liquidity needs given the allocation of proceeds to working capital.